Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

110.10EUR
22 Sep 2017
Change (% chg)

€-0.30 (-0.27%)
Prev Close
€110.40
Open
€110.10
Day's High
€111.15
Day's Low
€109.85
Volume
1,560,910
Avg. Vol
1,885,113
52-wk High
€123.90
52-wk Low
€86.03

Latest Key Developments (Source: Significant Developments)

Bayer ‍appoints Sharon James Head of Global Innovation & Development for Consumer Health
Friday, 22 Sep 2017 07:31am EDT 

Sept 22 (Reuters) - BAYER AG :‍APPOINTS SHARON JAMES HEAD OF GLOBAL INNOVATION & DEVELOPMENT FOR CONSUMER HEALTH​.  Full Article

Bayer gets positive CHMP opinion to update rivaroxaban's label
Friday, 15 Sep 2017 08:03am EDT 

Sept 15 (Reuters) - BAYER AG ::RECEIVES POSITIVE CHMP OPINION FOR RIVAROXABAN 10 MG ONCE DAILY FOR EXTENDED PREVENTION OF VENOUS THROMBOEMBOLISM.‍FINAL EUROPEAN COMMISSION DECISION EXPECTED BY NOVEMBER 2017​.  Full Article

FDA approves new treatment for adults with relapsed follicular lymphoma
Thursday, 14 Sep 2017 01:02pm EDT 

Sept 14 (Reuters) - U.S. Food and Drug Administration::U.S. FDA approves new treatment for adults with relapsed follicular lymphoma.Granted the approval of Aliqopa to Bayer Healthcare Pharmaceuticals, Inc​.Granted accelerated approval to Aliqopa for treatment of adults with relapsed follicular lymphoma who have received at least 2 prior treatments.  Full Article

Bayer and Ginkgo Bioworks join forces for sustainable agriculture
Thursday, 14 Sep 2017 07:01am EDT 

Sept 14 (Reuters) - Bayer Ag ::Bayer and Ginkgo Bioworks join forces for sustainable agriculture, forming new company with usd 100 million series a.Bayer AG - ‍Bayer and Ginkgo bioworks will create a new company focused on plant microbiome​.  Full Article

ASML announces CFO Wolfgang Nickl to leave by end of April 2018‍
Tuesday, 12 Sep 2017 06:02am EDT 

Sept 12 (Reuters) - ASML HOLDING NV ::CFO WOLFGANG NICKL TO LEAVE ASML BY THE END OF APRIL 2018‍​.‍WOLFGANG NICKL WILL JOIN GERMAN LIFE SCIENCE COMPANY BAYER <<>> AS ITS NEW CFO.​.  Full Article

Bayer and Vanderbilt University Medical Center agree five-year research alliance
Monday, 11 Sep 2017 08:05am EDT 

Sept 11 (Reuters) - BAYER AG ::‍BAYER AND VANDERBILT UNIVERSITY MEDICAL CENTER COLLABORATE TO DEVELOP THERAPIES AGAINST KIDNEY DISEASES​.‍BAYER WILL HAVE AN OPTION FOR EXCLUSIVE USE OF COLLABORATION RESULTS​.AGREED ON A FIVE-YEAR STRATEGIC RESEARCH ALLIANCE TO JOIN FORCES IN FIGHT AGAINST KIDNEY DISEASES.‍FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED​.  Full Article

Bayer submits U.S. license application for Hemophilia treatment
Thursday, 31 Aug 2017 12:35am EDT 

Aug 31 (Reuters) - Bayer AG :Says submits biologics license application in U.S. for BAY94-9027.  Full Article

Bayer says will continue to work with European Commission
Tuesday, 22 Aug 2017 09:03am EDT 

Aug 22 (Reuters) - Bayer Ag :‍confirmed that european commission has initiated a phase ii investigation of proposed combination of bayer and monsanto.says will continue to work constructively with the European Commission​.  Full Article

Bayer and SICIT 2000 sign exclusive distribution agreement‍​
Friday, 11 Aug 2017 08:43am EDT 

Aug 11 (Reuters) - BAYER AG :BAYER AND SICIT 2000 SIGN EXCLUSIVE DISTRIBUTION AGREEMENT‍​.FINANCIAL TERMS WERE NOT DISCLOSED‍​.UNDER THE AGREEMENT, BAYER WILL COMMERCIALIZE BAYFOLAN COBRE AND BAYFOLAN AKTIVATOR FOR FOLIAR USES IN VARIOUS CROPS WORLDWIDE.  Full Article

Compugen discloses updates to collaborative activities with Bayer in immuno-oncology
Wednesday, 26 Jul 2017 07:09am EDT 

July 26 (Reuters) - Compugen Ltd ::Compugen discloses updates to collaborative activities with bayer in immuno-oncology.Compugen - agreement with Bayer AG involves research, development, commercialization of antibody-based therapeutics against cgen-15001t and cgen-15022.Compugen Ltd - it has been determined current collaboration will focus solely on cgen-15001t, all rights to cgen-15022 will be returned to Compugen.  Full Article

BRIEF-Bayer ‍appoints Sharon James Head of Global Innovation & Development for Consumer Health

* ‍APPOINTS SHARON JAMES HEAD OF GLOBAL INNOVATION & DEVELOPMENT FOR CONSUMER HEALTH​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)